智通财经APP获悉,同源康医药-B(02410)午后涨超4%,截至发稿,涨3.87%,报14.21港元,成交额5940.29万港元。
消息面上,同源康医药发布公告,本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心拟纳入优先审评品种名单,拟定适应症为:具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变,并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。
智通财经APP获悉,同源康医药-B(02410)午后涨超4%,截至发稿,涨3.87%,报14.21港元,成交额5940.29万港元。
消息面上,同源康医药发布公告,本公司在研1类新药甲磺酸艾多替尼片(TY-9591片)被国家药品监督管理局(NMPA)药品审评中心拟纳入优先审评品种名单,拟定适应症为:具有表皮生长因子受体(EGFR)外显子19缺失 (19DEL)或外显子21(L858R)置换突变,并伴有中枢神经系统(CNS)转移的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.